Loading
A phase 1/2 trial of IDX-1197+XELOX in gastric & gastro-oesophageal junction cancer, run by Idience Co., Ltd., active and no longer recruiting.
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer is a phase 1/2 interventional study registered as NCT04725994 by Idience Co., Ltd., with 87 participants enrolled, started 2021-06-28 and due to reach its primary completion in 2026-07-31. Interventions recorded: IDX-1197+XELOX and IDX-1197+Irinotecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oxaliplatin, Platinum agents, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/